[Indications for the use of tactivin in the combined treatment of phlegmons of the maxillofacial area].

Abstract

The effects of subcutaneous and endolymphatic tactivin (in doses of 1 ml of 0.01% solution daily for 7 days) on clinical and immunological parameters were studied in patients with acute inflammations in the maxillofacial area, running a normo-, hypo-, and hyperergic course. Tactivin accelerated the arrest of inflammatory process and improved the patients' status, particularly so in cases with the hypo- and hyperergic inflammations. The key role in the mechanism of the drug action is played by increase of the immunoregulatory index, which reflects the increasing resistance of the body.

• Authors: V Iu Drobyshev, A I Volozhin, V S Agapov, T I Sashkina
• Journal: Stomatologiia (Stomatologiia (Mosk)) Vol. 75 Issue 4 Pg. 27-30 ( 1996) ISSN: 0039-1735 [Print] Russia (Federation)
• Vernacular Title: Pokazaniia k primeneniiu taktivina v kompleksnom lechenii flegmon cheliustno-litsevoĭ oblasti.
• PMID: 8992659 (Publication Type: English Abstract, Journal Article)

Chemical References

• Adjuvants, Immunologic
• Peptides
• Thymus Extracts
• T-activin

Topics

• Acute Disease
• Adjuvants, Immunologic (administration & dosage)
• B-Lymphocytes (drug effects, immunology)
• Cellulitis (drug therapy, immunology)
• Combined Modality Therapy
• Drug Evaluation
• Face
• Humans
• Immunity, Cellular (drug effects)
• Jaw Diseases (drug therapy, immunology)
• Peptides (administration & dosage)
• T-Lymphocytes (drug effects, immunology)
• Thymus Extracts (administration & dosage)